APRE stock icon

Aprea Therapeutics
APRE

$4.41
4.15%
 

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Employees: 7

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

147% more capital invested

Capital invested by funds: $4.35M [Q4 2023] → $10.8M (+$6.41M) [Q1 2024]

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

21% more funds holding

Funds holding: 19 [Q4 2023] → 23 (+4) [Q1 2024]

18.68% more ownership

Funds ownership: 24.76% [Q4 2023] → 43.44% (+18.68%) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$11
150%
upside
Avg. target
$17
286%
upside
High target
$20
354%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
354%upside
$20
Buy
Reiterated
14 May 2024
Wedbush
Robert Driscoll
150%upside
$11
Outperform
Maintained
27 Mar 2024
HC Wainwright & Co.
Joseph Pantginis
354%upside
$20
Buy
Maintained
26 Mar 2024

Financial journalist opinion